(Glecaprevir + pibrentasvir) is a Small Molecule owned by AbbVie, and is involved in 59 clinical trials, of which 49 were completed, 9 are ongoing, and 1 is planned.

Glecaprevir (ABT-493) is a NS3/4A protease inhibitor. Protease inhibitors prevent proteases from splitting proteins into peptides. HCV NS3, a protein with serine protease domain mediates the cleavage of the HCV polyprotein to release the functional proteins that are essential for viral propagation. The inhibition of NS3 protease activity is expected to block HCV replication in infected host cells.

Pibrentasvir (ABT-530) is a NS5A, NF5A inhibitor. The HCV NS5A protein is an essential component of the RNA replicase. NS5A is a pleiotropic protein with key roles in both viral RNA replication and modulation of the physiology of the host cell. NF kappa 5A suppresses TRAF2 dependent NF-B activation via interaction with NF5A and TRAF2, but suppress neither MEK1 activation nor IKK-beta dependent NF-kappa B activation.

The revenue for (Glecaprevir + pibrentasvir) is expected to reach a total of $18.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Glecaprevir + pibrentasvir) NPV Report.

(Glecaprevir + pibrentasvir) was originated by Abbott Laboratories and Enanta Pharmaceuticals and is currently owned by AbbVie.

(Glecaprevir + pibrentasvir) Overview

Glecaprevir and pibrentasvir (Maviret, Mavyret) is a fixed dose combination drug, acts as antiviral agent. It is formulated as film coated tablets, coated granules and pellets for oral route of administration. Maviret is indicated for the treatment of hepatitis C virus infection in adults. Mavyret is indicated to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also approved for adult patients with HCV genotype 1 infection who have been previously treated with a regimen either containing an NS5A inhibitor or an NS3/4A protease inhibitor but not both, and also indicated for treatment of all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17 and treatment of chronic hepatitis C (HCV)  with naive, compensated cirrhotic, genotype (GT)1, 2, 4, 5, and 6 infection patients. Maviret is indicated for the improvement of viremia in pediatric patients 3 years or older, with chronic hepatitis C or compensated cirrhosis type C. Mavyret is indicated for the treatment of adults and children aged 3 years and older or weighing at least 99 pounds who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis and have not been previously treated for HCV (treatment-naive).

The fixed dose combination of glecaprevir (ABT-493) with pibrentasvir (ABT-530) is under development for the treatment of hepatitis C virus infection for adults in the Asia.

AbbVie Overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.

The company reported revenues of (US Dollars) US$56,197 million for the fiscal year ended December 2021 (FY2021), an increase of 22.7% over FY2020. In FY2021, the company’s operating margin was 31.9%, compared to an operating margin of 24.8% in FY2020. In FY2021, the company recorded a net margin of 20.5%, compared to a net margin of 10.1% in FY2020. The company reported revenues of US$14,812 million for the third quarter ended September 2022, an increase of 1.6% over the previous quarter.

Quick View – (Glecaprevir + pibrentasvir)

Report Segments
  • Innovator (NME)
Drug Name
  • (Glecaprevir + pibrentasvir)
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.